Brits buy Dorland Global in $20M deal

Share this article:
Publicly held Huntsworth PLC, based in London, has purchased Dorland Global Corp., for $20.7 million in cash, extending the reach of its healthcare division into the US market.

The acquisition covers its two units, Dorland Global Health Communications and Dorland Global Public Relations.

The sale price for the previously independent agency will be shared by 10 shareholders, along with co-founders Harry and Rita Sweeney. The deal also may include deferred compensation based on Dorland profits for the year ending Dec. 31, 2007, plus a payment to be made based on three-year profits through 2010, Huntsworth said.

The maximum price was capped at $50 million. Dorland reported 2006 gross profit of $3.5 million and gross assets of $11 million as of year end.
The existing management team will continue to operate the business, reporting to David Rowley, chief executive of Huntsworth Health.

Dorland will serve as a US footprint for the Huntsworth Health division, the largest healthcare firm in the UK.

In an interview with MM&M, Rita Sweeney said being part of a larger agency will help Dorland “take on and pitch and win larger global accounts…that was the whole strategy to begin with.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...